Abstract. We attempted to find a specific antigen of oral squamous cell carcinoma (SCC) cells that could be safely applied to gene therapy in the conservative clinical treatment of oral cancer. We performed subtraction using normal human keratinocyte cells, followed by selection using four oral SCC cell lines. We isolated three clones from poorly differentiated SCC cells and four from well-differentiated SCC cells. These seven clones adsorbed to the oral SCC cells at rates 10-100 times those of normal human keratinocyte cells. The three clones from the poorly differentiated SCC cells showed the same peptide sequence (LAPRTHP). Of the four clones from the well-differentiated SCC cells, three showed the same peptide sequence (FGTLPGT) and the fourth showed a different one (VTPNSTP). Each peptide sequence may recognize the material that exists specifically on the oral SCC cell cortex. We can expect applications not only for tumortargeting treatment using a gene therapy virus vector but also for diagnosis using, as a tumor marker, the peculiar SCC surface material that these peptides recognize.
Introduction
In the treatment of oral cancers, the preservation of aesthetic features and functions is critical. Conservative treatments for oral cancers usually consist of radiotherapy, chemotherapy, and thermotherapy. The great advantage of radiotherapy combined with chemotherapy and/or thermotherapy is that it allows the oral function and facial configuration of patients to be well preserved. However, it is now difficult to cure advanced cases with only conservative or surgical treatment. Therefore, conservative therapy for oral cancers should be further developed. However, few studies exist on the use of conservative combination therapy in treating oral cancers. We have also tried to establish a conservative treatments that combine radiotherapy, chemotherapy, thermotherapy, immunotherapy, and gene therapy in oral cancer (1) (2) (3) (4) (5) (6) (7) . Those studies reported on the usefulness of wild-type p53-bearing adenovirus vectors in a combination of radiotherapy, thermotherapy, and thermoradiotherapy (therapy combining hyperthermia with radiotherapy) to treat cell lines of human oral squamous cell carcinoma (SCC) and salivary gland adenocarcinoma (1, (3) (4) (5) . However, to clinically apply the wild-type p53-bearing adenovirus vector to the treatment of human oral cancer, several problems must be solved. The utility of gene delivery vectors is limited by the nonselective nature in which the vectors, either nonviral or viral, interact with the cell surface, resulting in the transduction of numerous cell types in addition to the target cells (8) . Thus, the wild-type p53-bearing adenovirus vector is not specific to the cancer cell and is considered capable of damaging normal cells. The surface of a cell is a landscape of macromolecules that are specific to the function and state of the cell (9-11). The ligands for specific macromolecules can serve as targeting agents, assuming they have specificity for the cell type (12) (13) (14) . Further development and general application of gene therapy will depend on the ability to target delivery vectors to tissues of interest and limit uptake by healthy tissues. Redirecting the vectors to other tissues has not yet been successful; therefore, targeting ligands are needed. Targeting may in some cases be done by an ex vivo procedure, but direct i.v. injection of organhoming complexes would be far less invasive and elaborate (12) .
In the present study, we attempted to find a specific antigen for oral SCC cells that could be applied to gene therapy in clinical treatment. Phage display. Phage libraries were amplified, purified, and titered according to the manufacturer's protocols. Biopanning (or affinity selection) is a purifying technique involving subtraction/selection cycles. Specifically, the target cells were plated into 96-well plates and cultured until 1 or 2 days after confluence; then 2x10 11 pfu of input phage library was used to pan confluent cultures of target cells (passages 2 to 4) in duplicate. Before biopanning, the growth medium was changed to 1 ml DMEM containing 1% BSA, and the plates of the target cells were incubated at 4˚C for 15 min.
Materials and methods

Cell
First, we biopanned the HEK cells for three rounds (subtraction cycle) and made a culture of the phage library with HEK cells without binding specificity. For HEK cells, 2x10 11 pfu of precleared or stock phage library was incubated with cells for 1 h at 4˚C. Cells were washed 5 times in icecold PBS/1% BSA for 5 min per wash. Weakly associated phages were eluted in 1 ml 0.2 mol/l glycine (pH 2.2) for 10 min on ice, followed by neutralization with 200 μl TrisHCl (pH 8.0). High-affinity phages (tightly bound phages) were isolated by lysing the cells in 1 ml of 30 m mol/l TrisHCl/1 m mol/l EDTA (pH 8.0) for 1 h on ice. Each well was filled completely with blocking buffer [0.1M NaHCO 3 (pH 8.6), 0.5% BSA, 0.02% NaN 3 ], then incubated for 1 h at 4˚C. After the buffer was discarded, each well was washed 6 times with PBS. The subtracted phage supernatant was skimmed onto each well and rocked gently for 60 min at room temperature. The subtracted supernatant was recovered and used to resuspend other subtraction cells. This subtraction cycle was repeated 3 times in total.
Next, we biopanned the four human oral SCC cell lines for three rounds (selection cycle) using well-and poorly differentiated SCC cells, respectively, and in succession. The HSC2 and HSC4 cells originated from well-differentiated oral SCC cells. The HSC3 and SAS cells originated from poorly differentiated SCC cells. Each well containing four SCC cells was filled completely with blocking buffer then incubated for 1 h at 4˚C. After the buffer was discarded, each well was washed 6 times with PBS. The subtracted phage supernatant was skimmed onto each well and rocked gently for 60 min at room temperature. The plates were washed for 10 min with PBS. To block nonspecific binding, each well was filled with 0.2 M glycine-HCl (pH 2.2), 1 mg/ml BSA, and was rocked gently for no more than 10 min. Then each well was neutralized with 15 μl of 1 M Tris-HCl (pH 9.1). To obtain the cell-surface antigen specific to the well-differentiated SCC cells, the subtracted phage supernatant was reacted first to the HSC2 cells, and then to the HSC4 cells. In a similar way, to obtain the cell-surface antigen specific to the poorly differentiated SCC cells, the subtracted phage supernatant was reacted first to the SAS cells, and then to HSC3 cells. Cell debris was removed and the supernatant was restored. Phages were amplified and titered between each round to ensure 10 MOI per titer of the target cells.
Plaque amplification. After completion of biopanning, Escherichia coli (E. coli) ER2738 was infected with the resulting phages and plated, and individual plaques were picked, amplified, and sequenced. The E. coli ER2738 strain was cultured in LB medium overnight. The subtracted/selected phage supernatants were titered on LB/IPTG/X gel plates. The plaques from this titering could be used for sequencing. Using a sterile wooden stick, blue plaques were stabbed and transferred to the tubes containing ER2738 culture. A total of 40 clones were gathered, 20 clones of well-differentiated SCC cells and 20 clones of poorly differentiated SCC cells, and then they were amplified with the LB medium, a titration stripes lingua. Afterwards, peculiar phages were gathered or an adsorption bioassay was performed. Tubes were incubated at 37˚C with shaking for 4.5 h. The cultures were centrifuged, and the upper 80% of the supernatants were stored as the amplified phage stock.
Reconfirmation of phage clone specifity. Cell debris was removed and the supernatant recovered. Phages were amplified and titered between each round to ensure that 10 9 pfu of input phages was used at the start of each successive round. After completion of biopanning, E. coli ER2738 was infected with the resulting phages and plated, and individual plaques were picked, amplified, and sequenced. For further binding studies, high-titer homogeneous populations of each phage were prepared. Briefly, 1x10 7 pfu of each phage was biopanned on SCC and HEK cells for 30 min at 4˚C. Unbound phages were removed by stringent washing, and the resulting cellassociated phages were titered. The percentage recovery was calculated for each cell type with a peptideless phage to allow for background binding. In the four kinds of oral SCC and HEK cells, the selection was performed by gradually changing the density of the phage liquid of each of the 40 clones. The collected phage was infected with E. coli, of plaque formations were counted, and the percentage of adsorbed phages under the same density was calculated.
Results
In the 40 clones, the phages that were adsorbed to the oral SCC cells at a rate 10-100 times the rate of HEK cells included three clones from the poorly differentiated SCC cells and four from the well-differentiated SCC cells. The peptide sequence of the adsorption parts in the SCC of each of these seven clones was analyzed with a sequencer. All three phage clones from the poorly differentiated SCC cells showed the same DNA base sequence (Type I). The DNA base sequence of Type I was 'AGG ATG AGT CCG CGG AGC AAG' (Fig. 1) . Of the four clones from the well-differentiated SCC cells, three were the same sequence (Type II) and one had a different sequence (Type III) (Figs. 2 and 3) . The DNA base sequence of Type II was AGG ATG AGT CCG CGG AGC AAG (Fig. 2) . The DNA base sequence of Type III was AGG ATG AGT CCG CGG AGC AAG (Fig. 3) .
Discussion
Gene therapy has the potential to play an important role in both immediate and indirect cancer treatment. It is necessary to introduce a gene exclusively into cancer cells in order to ensure its beneficial effect. It is not sufficient to infect cancer cells, though the method of infecting cells with a gene by a virus vector is often adopted (5) . The discovery of materials that bind specifically to cancer cells, and that can thus be used in cell-specific gene or drug delivery, is crucial for improved cancer diagnosis and therapy (16) (17) (18) (19) .
In the present study, we attempted to find a specific antigen of oral SCC cells that could be safely applied to gene therapy in the conservative clinical treatment of oral cancer. We performed subtraction using normal cells (HEK cells), followed by a selection using four oral SCC cell lines. As a result, we isolated three clones from poorly differentiated SCC cells and four from well-differentiated SCC cells that adsorbed to the oral SCC cells at rates 10-100 times greater than those of HEK cells. The three clones from the poorly differentiated SCC cells had the same base sequence, AGG ATG AGT CCG CGG AGC AAG. Of the four clones obtained from the well-differentiated SCC cells, three had the same base sequence AGG ATG AGT CCG CGG AGC AAG, and the fourth had a different one, AGG ATG AGT CCG CGG AGC AAG.
First, the DNA base sequence is converted into the base sequence of complementary mRNA, and then the peptide sequence is decided by reading the mRNA from the counterdirection, as follows: The DNA base sequence of Type I is AGG ATG AGT CCG CGG AGC AAG. The complementary DNA base sequence is UCC UAC UCA GGC GCC UCG UUC. The peptide sequence is CUU(L) GCU(A) CCG(P) CGG(R) ACU(T) CAU(H) CCU(P) (LAPRTHP). The DNA base sequence of Type II is CGT CCC AGG AAG AGT ACC AAA. The complementary DNA base sequence is GCA GGG UCC UUC UCA UGG UUU. The peptide sequence is UUU(F) GGU(G) ACU(T) CUU(L) CCU(P) GGG(G) ACG(T) (FGTLPGT). The DNA base sequence of Type III is AGG AGT AGA ATT AGG AGT AAC. The complementary DNA base sequence is UCC UCA UCU UAA UCC UCA UUG. The peptide sequence is GUU(V) ACU(T) CCU(P) AAU(N) UCU(S) ACU(T) CCU(P) (VTPNSTP). As a result, we isolated three types of peptide sequences: LAPRTHP, FGTLPGT, and VTPNSTP. Each peptide sequence may recognize the material that exists specifically on the oral SCC cell cortex.
Before starting in vivo application of these peptides, we should confirm what kinds of specificity are included in the phage clones isolated in this study against many types of human culture cells, including SCC, using Phage ELISA. In case these peptides are applied to the diagnosis, we can apply the phage ELISA in vivo as we do for the diagnosis of SCC, and make antibodies to each peptide for the histopathological diagnosis. In addition, radionuclide techniques may allow us to diagnose SCC at an early stage by combining a suitable radioisotope with these monoclonal antibodies. When we apply these peptides to treatment, we can expect greater specific gene therapy for oral cancer by combining these SCC-specific phages with the p53 adenovirus vector. Thus, we can expect application not only to tumor-targeting treatments using gene therapy virus vectors but also to diagnosis using as a tumor marker the particular SCC surface material that these peptides recognize, although comparison in an in vivo experiment is also necessary.
